Raymond James Maintains Their Hold Rating on Aerie Pharma (AERI)

Raymond James analyst Elliot Wilbur maintained a Hold rating on Aerie Pharma (AERIResearch Report) today. The company’s shares closed last Monday at $18.41.

According to TipRanks.com, Wilbur has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.6% and a 42.0% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $27.25 average price target.

See today’s analyst top recommended stocks >>

Aerie Pharma’s market cap is currently $883.4M and has a P/E ratio of -4.80. The company has a Price to Book ratio of 37.13.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.